XVIE to Treat Androgenetic Alopecia (AGA)

Inclusion Criteria: * Male or female, aged 18 to 70 years (inclusive) at the time of informed consent * Able to understand and voluntarily provide written informed consent * Willing and able to comply with study procedures, including all scheduled visits and assessments * In good general health as determined by the Investigator based on medical history and screening assessments * Clinical diagnosis of androgenetic alopecia (AGA) with documented hair loss for at least 6 months prior to screening * Stable pattern of hair loss (no rapid progression) for at least 6 months prior to screening * Male subjects: Norwood-Hamilton Classification Stage III, IIIa, IIIv, IV, or IVa * Female subjects: Ludwig Classification Stage I or II * Normal thyroid function (TSH within normal limits) at screening, or stable on thyroid replacement therapy for at least 6 months * Ferritin level within normal limits at screening, or documented adequate iron stores * No clinically significant abnormalities on CBC with differential or comprehensive metabolic panel (CMP) at screening outside protocol-defined eligibility thresholds * Female subjects of childbearing potential must have a negative urine pregnancy test at screening and agree to use an effective method of contraception throughout the study and for 30 days after the last treatment * Female subjects who are postmenopausal (no menses for at least 12 months) or surgically sterile are not required to use contraception Exclusion Criteria: * Use of t…